Literature DB >> 25990004

The age-risk relationship of hematologic malignancies in patients with rheumatoid arthritis: a nationwide retrospective cohort study.

Yu-Chih Lin1, Hui-Wen Chou, Wen-Chan Tsai, Jeng-Hsien Yen, Shun-Jen Chang, Yi-Ching Lin.   

Abstract

The risk of hematologic malignancies in rheumatoid arthritis (RA) patients has been an important clinical concern. The information of age effect on the interval from the diagnosis of RA to that of hematologic malignancies is limited. This study aimed to define the age-risk relationship between hematologic malignancies and RA. A retrospective cohort study was conducted nationwide with 17,472 patients and 87,360 controls from the Taiwan National Health Insurance Database covering 1997-2008. The subsequent development of hematologic malignancy was observed. The age-adjusted standardized incidence ratios (SIRs), incidence per 1000 person-years, follow-up duration for the diagnosis of hematologic malignancies, and cumulative hazard rates of hematologic malignancies between RA and controls were analyzed. Significantly higher incidences of both lymphoid and myeloid malignancies were found in male RA patients compared with RA-free patients (SIR 3.36, 95% CI = 2.03-5.57, and SIR: 3.69, 95% CI = 2.46-5.53). A significantly increased overall incidence risk was found in lymphoid malignancies (SIR 3.00, 95% CI = 2.22-4.05) but not significantly increased in myeloid malignancies (SIR 1.54, 95% CI = 0.95-2.50) in female RA. The follow-up duration for hematologic malignancies was significantly shorter in RA patients than in RA-free patients in both males and females (70.70 vs. 103.80 months and 67.73 vs. 100.93 months, respectively). Additionally, higher cumulative hazard rates in both lymphoid and myeloid malignancies were found in male RA patients (p < 0.0001). RA patients have a shorter incubation time to hematological malignancies while comparing to the RA-free people, and the risks are variable in gender and different age groups.

Entities:  

Mesh:

Year:  2015        PMID: 25990004     DOI: 10.1007/s10067-015-2972-4

Source DB:  PubMed          Journal:  Clin Rheumatol        ISSN: 0770-3198            Impact factor:   2.980


  32 in total

1.  Myelodysplastic syndrome associated with low-dose methotrexate in rheumatoid arthritis.

Authors:  Hiroshi Okamoto; Masanao Teramura; Naoyuki Kamatani
Journal:  Ann Pharmacother       Date:  2004-01       Impact factor: 3.154

Review 2.  Anti-tumor necrosis factor alpha therapy and the risk of lymphoma in rheumatoid arthritis: no clear answer.

Authors:  Deborah P M Symmons; Alan J Silman
Journal:  Arthritis Rheum       Date:  2004-06

Review 3.  Malignant lymphomas in autoimmunity and inflammation: a review of risks, risk factors, and lymphoma characteristics.

Authors:  Karin Ekström Smedby; Eva Baecklund; Johan Askling
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2006-11       Impact factor: 4.254

Review 4.  Lymphocyte transformation and autoimmune disorders.

Authors:  C Tarella; A Gueli; M Ruella; A Cignetti
Journal:  Autoimmun Rev       Date:  2012-12-04       Impact factor: 9.754

5.  Malignant lymphoma-associated autoimmune diseases--a descriptive epidemiological study.

Authors:  László Váróczy; Lajos Gergely; Margit Zeher; Gyula Szegedi; Arpád Illés
Journal:  Rheumatol Int       Date:  2002-08-29       Impact factor: 2.631

6.  Polymorphism within the second intron of the IL-1 receptor antagonist gene in patients with hematopoietic malignancies.

Authors:  J Demeter; G Messer; S Rämisch; J B Mee; F S di Giovine; M Schmid; F Herrmann; F Porzsolt
Journal:  Cytokines Mol Ther       Date:  1996-12

7.  Do rheumatoid arthritis and lymphoma share risk factors?: a comparison of lymphoma and cancer risks before and after diagnosis of rheumatoid arthritis.

Authors:  Karin Hellgren; Karin E Smedby; Nils Feltelius; Eva Baecklund; Johan Askling
Journal:  Arthritis Rheum       Date:  2010-05

Review 8.  Considerations with the use of biological therapy in the treatment of rheumatoid arthritis.

Authors:  Roy M Fleischmann; Imran Iqbal; Richard L Stern
Journal:  Expert Opin Drug Saf       Date:  2004-09       Impact factor: 4.250

9.  Lymphoma developing in a patient with rheumatoid arthritis taking low dose weekly methotrexate.

Authors:  M H Ellman; H Hurwitz; C Thomas; M Kozloff
Journal:  J Rheumatol       Date:  1991-11       Impact factor: 4.666

10.  Myelodysplastic and myeloproliferative syndromes associated with giant cell arteritis and polymyalgia rheumatica: a coincidental coexistence or a causal relationship?

Authors:  G Espinosa; J Font; F J Muñoz-Rodríguez; R Cervera; M Ingelmo
Journal:  Clin Rheumatol       Date:  2002-08       Impact factor: 2.980

View more
  3 in total

1.  Malignancy as a comorbidity in rheumatic diseases: a retrospective hospital-based study.

Authors:  Hai-Long Wang; Yong-Ming Zhou; Guang-Zhao Zhu; Zhu Yang; Bao-Jin Hua
Journal:  Clin Rheumatol       Date:  2017-05-16       Impact factor: 2.980

2.  The impact of cancer development on the risk of mycobacterial diseases among rheumatoid arthritis patients.

Authors:  S-W Pan; Y-F Yen; Y R Kou; P-H Chuang; J-Y Feng; Y-J Chan; W-J Su
Journal:  Epidemiol Infect       Date:  2017-07-24       Impact factor: 4.434

3.  Alterations of gut fungal microbiota in patients with rheumatoid arthritis.

Authors:  Xiaoyu Sun; Yushuang Wang; Xinke Li; Meiling Wang; Jianyi Dong; Wei Tang; Zengjie Lei; Yuling Guo; Ming Li; Yuyuan Li
Journal:  PeerJ       Date:  2022-03-01       Impact factor: 2.984

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.